ABSTRACT:
Background: Breast cancer has increased universally. Angiogenesis is an essential step for cancer growth, progression and metastasis. Recent studies have focused on Angiopoietin-2 as a promising biomarker in prospecting the prognosis of the cancer. Objective: Determine the relation between serum concentrations of Angiopoietin-2 and clinicopathological data in breast cancer patients. Methodology: This study is prospective, cohort type. It includes 30 women with breast cancer, who met the study criteria. The serum Ang-2 value was calibrated using ELISA technique. The data was processed using SPSS program. Results: Ang-2 serum levels were statistically significant associated with ER status (P = 0.036). However, no signifi¬cant correlation was observed between serum Ang-2 level and the other clinicopathologic param¬eters tested, including Histological type (P = 0.417), Clinical grade G (P = 0.91), Clinical stage T (P = 0.913), Clinical stage N (P = 0.086), PR status (P = 0.467), and HER-2 status (P = 0.791). Serum levels of Ang-2 for breast cancer patients was significantly higher than healthy control (20411.33± 6283.19 vs 1731.70± 368.35 pg/ml, P< 0.000). our data indicates that serum levels of Ang-2 has no correlation between the tumor grade and stage in breast cancer patients.
Cite this article:
Majd Haidar, Jumana Al Saleh. Determination of Serum Angiopioetin-2 levels in Breast cancer patients at Damascus University Hospitals. Research Journal of Pharmacy and Technology. 2021; 14(9):4856-8. doi: 10.52711/0974-360X.2021.00843
Cite(Electronic):
Majd Haidar, Jumana Al Saleh. Determination of Serum Angiopioetin-2 levels in Breast cancer patients at Damascus University Hospitals. Research Journal of Pharmacy and Technology. 2021; 14(9):4856-8. doi: 10.52711/0974-360X.2021.00843 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-9-57
REFERENCES:
1. Li, P., et al., Diagnostic and prognostic potential of serum angiopoietin-2 expression in human breast cancer. International Journal of Clinical and Experimental Pathology, 2015; 8(1): p. 660.
2. Sun, Y.-S., et al., Risk factors and preventions of breast cancer. International Journal of Biological Sciences, 2017; 13(11): 1387.
3. Xu, Y., et al., The role of serum angiopoietin-2 levels in progression and prognosis of lung cancer: A meta-analysis. Medicine, 2017; 96(37).
4. Barron, G.A., et al., Circulating levels of angiogenesis-related growth factors in breast cancer: A study to profile proteins responsible for tubule formation. Oncology Reports, 2017; 38(3): 1886-1894.
5. Srirajaskanthan, R., et al., Circulating angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis. Endocrine-Related Cancer, 2009; 16(3): 967-976.
6. Souma, T., et al., Context-dependent functions of angiopoietin 2 are determined by the endothelial phosphatase VEPTP. Proceedings of the National Academy of Sciences, 2018; 115(6): 1298-1303.
7. Gillen, J., D. Richardson, and K. Moore, Angiopoietin-1 and Angiopoietin-2 inhibitors: Clinical development. Current oncology reports, 2019; 21(3): 22.
8. Engin, H., et al., Plasma concentrations of Ang-1, Ang-2 and Tie-2 in gastric cancer. European Cytokine Network, 2012; 23(1): 21-24.
9. Kim, H., et al., Oncogenic function of angiopoietin-2 in vitro and its modulation of tumor progression in colorectal carcinoma. Oncology Letters, 2017; 14(1): 553-560.
10. Daly, C., et al., Angiopoietins bind thrombomodulin and inhibit its function as a thrombin cofactor. Scientific Reports, 2018; 8(1): 1-12.
11. Zhang, Y., et al., Angiopoietin-Tie signaling pathway in endothelial cells: a computational model. iScience, 2019; 20: 497-511.
12. Fagiani, E. and G. Christofori, Angiopoietins in angiogenesis. Cancer Letters, 2013; 328(1): 18-26.
13. Detjen, K.M., et al., Angiopoietin-2 promotes disease progression of neuroendocrine tumors. Clinical Cancer Research, 2010; 16(2): 420-429.
14. Sallinen, H., et al., Preoperative angiopoietin-2 serum levels: a marker of malignant potential in ovarian neoplasms and poor prognosis in epithelial ovarian cancer. International Journal of Gynecologic Cancer, 2010; 20(9).